Related Experiment Video

Updated: May 24, 2026

Characterization at the Molecular Level using Robust Biochemical Approaches of a New Kinase Protein
11:23

Characterization at the Molecular Level using Robust Biochemical Approaches of a New Kinase Protein

Published on: June 30, 2019

Recent findings confirm LIM domain kinases as emerging target candidates for cancer therapy

F Manetti1

  • 1Dipartimento Farmaco Chimico Tecnologico, Universita degli Studi di Siena, via Alcide de Gasperi 2, I-53100 Siena, Italy. fabrizio.manetti@unisi.it

Current Cancer Drug Targets
|March 15, 2012
PubMed

Insights

LIM domain kinases (LIMK1 and LIMK2) regulate actin cytoskeleton dynamics crucial for cell invasion. Targeting LIMK offers a potential therapeutic strategy against cancer metastasis.

Area of Science:

  • Cell Biology
  • Molecular Biology
  • Cancer Research

Background:

  • LIM domain kinases (LIMK1 and LIMK2) are key regulators of the actin cytoskeleton.
  • They control actin dynamics by modulating cofilin phosphorylation, influencing actin turnover and cell structure.
  • LIMK activity is influenced by numerous protein partners and signaling pathways.

Purpose of the Study:

  • To elucidate the role of LIMK1 and LIMK2 in actin cytoskeleton regulation.
  • To investigate the involvement of LIMK activators, such as Rho GTPases and their effectors, in cancer progression.
  • To evaluate LIMK as potential therapeutic targets for inhibiting tumor invasion and metastasis.

Main Methods:

  • Review of existing literature on LIMK signaling pathways.
  • Analysis of protein interactions and regulatory mechanisms of LIMK.
  • Exploration of the connection between LIMK activity and cancer cell invasion.

Main Results:

  • LIMK1 and LIMK2 are central to actin cytoskeleton regulation and cell motility.
  • Upstream signaling molecules like Rho GTPases and their effectors (ROCK, PAK, MK2) activate LIMK and promote cancer cell invasion.
  • LIMK activity is critical for the invasive and metastatic potential of tumor cells.

Conclusions:

  • LIM domain kinases are pivotal in regulating actin dynamics essential for cell invasion.
  • Targeting LIMK activity presents a promising strategy for developing novel anti-cancer therapeutics to combat tumor metastasis.
  • Modulating LIMK function could inhibit cancer cell invasion driven by various upstream signaling pathways.

More Related Videos

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...